United Therapeutics Stock Price, News & Analysis (NASDAQ:UTHR) $230.45 +0.06 (+0.03%) (As of 01:14 PM ET) Add Compare Share Share Today's Range$230.45▼$234.0350-Day Range$219.23▼$236.7752-Week Range$204.44▼$283.09Volume87,587 shsAverage Volume392,162 shsMarket Capitalization$10.83 billionP/E Ratio12.70Dividend YieldN/APrice Target$288.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability United Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside25.0% Upside$288.00 Price TargetShort InterestBearish2.40% of Shares Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment0.88Based on 4 Articles This WeekInsider TradingSelling Shares$6.81 M Sold Last QuarterProj. Earnings Growth12.81%From $19.44 to $21.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.53 out of 5 starsMedical Sector53rd out of 949 stocksPharmaceutical Preparations Industry19th out of 437 stocks 2.4 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $288.00, United Therapeutics has a forecasted upside of 25.0% from its current price of $230.45.Amount of Analyst CoverageUnited Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.40% of the outstanding shares of United Therapeutics have been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in United Therapeutics has recently increased by 4.63%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 3.3 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for United Therapeutics this week, compared to 4 articles on an average week.Search Interest6 people have searched for UTHR on MarketBeat in the last 30 days. MarketBeat Follows3 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,806,244.00 in company stock.Percentage Held by Insiders12.50% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 12.81% in the coming year, from $19.44 to $21.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 12.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.80.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 12.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 103.46.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About United Therapeutics Stock (NASDAQ:UTHR)United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More UTHR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UTHR Stock News HeadlinesNovember 28, 2023 | benzinga.comUnited Therapeutics Stock (NASDAQ:UTHR) Dividends: History, Yield and DatesNovember 26, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Given Average Rating of "Moderate Buy" by AnalystsNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 24, 2023 | finance.yahoo.comWhy United Therapeutics (UTHR) is a Top Momentum Stock for the Long-TermNovember 18, 2023 | finance.yahoo.comInsider Sell Alert: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United ...November 13, 2023 | finance.yahoo.comJim Simons Stock Portfolio: 12 Biggest Healthcare StocksNovember 8, 2023 | finance.yahoo.com3d Systems (DDD) Q3 2023 Earnings Call TranscriptNovember 3, 2023 | hk.finance.yahoo.comUnited Therapeutics Corp (UTHR) Reports 18% YoY Revenue Growth in Q3 2023November 29, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 2, 2023 | finance.yahoo.comUnited Therapeutics Corporation (NASDAQ:UTHR) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | markets.businessinsider.comStrong Demand for Tyvaso DPI and Potential Market Growth Underpin Buy Rating for UTHRNovember 2, 2023 | finance.yahoo.comQ3 2023 United Therapeutics Corp Earnings CallNovember 1, 2023 | bizjournals.comSilver Spring’s United Therapeutics betting big on organ manufacturing despite death of pig heart recipientNovember 1, 2023 | seekingalpha.comUnited Therapeutics Corporation 2023 Q3 - Results - Earnings Call PresentationNovember 1, 2023 | finance.yahoo.comUnited Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesNovember 1, 2023 | benzinga.comHealth Care Company United Therapeutics Announces Acquisition of Miromatrix MedicalNovember 1, 2023 | finance.yahoo.comUnited Therapeutics Corporation Reports Third Quarter 2023 Financial ResultsOctober 31, 2023 | bizjournals.comSilver Spring's United Therapeutics reaches $91M deal to buy Miromatrix MedicalOctober 31, 2023 | finance.yahoo.comUnited Therapeutics Corporation to Present at the UBS Biopharma Conference 2023October 31, 2023 | finance.yahoo.comUnited Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary FibrosisOctober 30, 2023 | bizjournals.comMiromatrix Medical acquired by United Therapeutics two years after IPOOctober 30, 2023 | businesswire.comUnited Therapeutics to Acquire Miromatrix MedicalOctober 25, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX) and United Therapeutics (UTHR)October 25, 2023 | finance.yahoo.comUnited Therapeutics Corporation to Report Third Quarter 2023 Financial Results Before the Market Opens on Wednesday, November 1, 2023October 23, 2023 | msn.comUnited Therapeutics Shifts Focus To Tyvaso DPI Amidst Generic ThreatOctober 22, 2023 | seekingalpha.comUnited Therapeutics: Both Fundamental And Technical Analyses Justify A Buy DecisionOctober 1, 2023 | finance.yahoo.comUnited Therapeutics Corporation's (NASDAQ:UTHR) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?See More Headlines Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees985Year Founded1996Price Target and Rating Average Stock Price Target$288.00 High Stock Price Target$314.00 Low Stock Price Target$230.00 Potential Upside/Downside+25.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$18.15 Trailing P/E Ratio12.69 Forward P/E Ratio11.90 P/E GrowthN/ANet Income$727.30 million Net Margins40.82% Pretax Margin52.52% Return on Equity17.10% Return on Assets13.79% Debt Debt-to-Equity Ratio0.09 Current Ratio4.65 Quick Ratio4.51 Sales & Book Value Annual Sales$1.94 billion Price / Sales5.59 Cash Flow$17.03 per share Price / Cash Flow13.53 Book Value$105.24 per share Price / Book2.19Miscellaneous Outstanding Shares46,990,000Free Float41,120,000Market Cap$10.83 billion OptionableOptionable Beta0.57 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Martine A. Rothblatt J.D. (Age 68)M.B.A., Ph.D., Founder, Chairman & CEO Comp: $5.32MMr. Michael I. Benkowitz (Age 51)President & COO Comp: $2.83MMr. James C. Edgemond (Age 55)CFO & Treasurer Comp: $2.01MMr. Paul A. Mahon J.D. (Age 59)Executive VP, General Counsel & Corporate Secretary Comp: $2.31MMr. Dewey Steadman C.F.A.Head of Investor RelationsMs. Holly HobsonAssociate Vice President of Human ResourcesKevin T. GraySenior Vice President of Strategic Operations & LogisticsMr. Patrick Poisson (Age 55)Executive VP of Technical Operations Dr. Leigh PetersonSenior Vice President of Product DevelopmentMr. Gil GoldenSenior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSBioMarin PharmaceuticalNASDAQ:BMRNImmunoGenNASDAQ:IMGNMadrigal PharmaceuticalsNASDAQ:MDGLAlnylam PharmaceuticalsNASDAQ:ALNYView All CompetitorsInsiders & InstitutionsDeutsche Bank AGSold 151,343 shares on 11/24/2023Ownership: 0.128%Graham Capital Management L.P.Bought 1,797 shares on 11/22/2023Ownership: 0.004%Comerica BankBought 150,989 shares on 11/21/2023Ownership: 0.333%Walleye Trading LLCBought 5,000 shares on 11/21/2023Ownership: 0.000%Walleye Capital LLCBought 2,400 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions UTHR Stock Analysis - Frequently Asked Questions Should I buy or sell United Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" UTHR shares. View UTHR analyst ratings or view top-rated stocks. What is United Therapeutics' stock price target for 2024? 8 Wall Street research analysts have issued 1 year price targets for United Therapeutics' stock. Their UTHR share price targets range from $230.00 to $314.00. On average, they anticipate the company's share price to reach $288.00 in the next year. This suggests a possible upside of 24.5% from the stock's current price. View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts. How have UTHR shares performed in 2023? United Therapeutics' stock was trading at $278.09 at the beginning of the year. Since then, UTHR shares have decreased by 16.8% and is now trading at $231.32. View the best growth stocks for 2023 here. When is United Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our UTHR earnings forecast. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) released its earnings results on Wednesday, November, 1st. The biotechnology company reported $5.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.28. The biotechnology company had revenue of $609.40 million for the quarter, compared to the consensus estimate of $585.82 million. United Therapeutics had a trailing twelve-month return on equity of 17.10% and a net margin of 40.82%. The company's revenue was up 18.1% compared to the same quarter last year. During the same period in the previous year, the company posted $4.91 earnings per share. What ETFs hold United Therapeutics' stock? ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Subversive Mental Health ETF (SANE), Invesco Pharmaceuticals ETF (PJP), First Trust NYSE Arca Biotechnology Index Fund (FBT), Inspire Faithward Mid Cap Momentum ETF (GLRY), Formidable Fortress ETF (KONG), First Trust Health Care AlphaDEX Fund (FXH) and Alpha Intelligent - Large Cap Value ETF (AILV). What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE). Who are United Therapeutics' major shareholders? United Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (5.54%), Palo Alto Investors LP (1.23%), Bank of New York Mellon Corp (1.22%), AQR Capital Management LLC (1.01%), Fuller & Thaler Asset Management Inc. (0.92%) and Northern Trust Corp (0.83%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:UTHR) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.